The European head of Japanese pharmaceutical firm Eisai Co., Ltd., has warned that it may cut investment in the UK, pharmaphorum reported on 29 November.
Citing poor commercial opportunities, the small size of the UK pharma market and issues with the National Institute for Health and Care Excellence, Gavin Hendler said, “We don’t feel that we are getting a good enough deal”.
Eisai has invested £1.3bn into the UK, including in a Hatfield, Hertfordshire, factory.